Wednesday’s Midday Movers: ImmunoCellular Therapeutics (IMUC), Northwest Biotherapeutics (NWBO), Enteromedics Inc. (ETRM), Tokai Pharma (TKAI), Exact Sciences (EXAS)

By Carrie Williams

So far Wednesday, November 16, NASDAQ is up 0.49% and the S&P is up 0.06%. Here are this morning’s most active stocks: ImmunoCellular Therapeutics (NYSE MKT:IMUC), Northwest Biotherapeutics (NASDAQ:NWBO), Enteromedics Inc. (NASDAQ:ETRM), Tokai Pharma (NASDAQ:TKAI) and Exact Sciences (NASDAQ:EXAS).

ImmunoCellular Therapeutics is down -16.25% in midday trading to $0.07. Shares opened today at $0.08. The company has a 52-week low of $0.07 and a 52-week high of $0.53. Over the last 3 months, the insider sentiment on ImmunoCellular Therapeutics has been neutral based on 5 corporate insider transactions. This sentiment is slightly lower than the average sector sentiment of insiders.

Northwest Biotherapeutics is up 14.38% in midday trading to $0.52. Shares opened today at $0.45. The company has a 52-week low of $0.32 and a 52-week high of $5.19.

Enteromedics Inc. is down -13.67% in midday trading to $0.05. Shares opened today at $0.06. The company has a 52-week low of $0.05 and a 52-week high of $2.95. Over the last 3 months, the insider sentiment on Enteromedics Inc. has been positive based on 4 corporate insider transactions. This sentiment is higher than the average sector sentiment of insiders.

Tokai Pharma is up 10.1% in midday trading to $1.10. Shares opened today at $1.00. The company has a 52-week low of $0.73 and a 52-week high of $11.92.

Exact Sciences is down -9.94% in midday trading to $15.49. Shares opened today at $17.20. The company has a 52-week low of $4.67 and a 52-week high of $22.80. On the Street’s front, the average 12-month analyst price target for the stock is $20.00, marking a 16.28% potential upside from current levels. In a report issued on November 9, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on EXAS, with a price target of $24, which implies an upside of 40% from current levels. Separately, on October 27, Roth Capital’s Chris Lewis reiterated a Hold rating on the stock and has a price target of $15. In the last 30 days, insiders have sold $20.31M worth of EXAS shares. Over the last 3 months, the insider sentiment on Exact Sciences has been positive based on 42 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.